Hasil Pencarian - N.S. Callander
- Menampilkan 1 - 3 hasil dari 3
-
1
P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY oleh A. Suvannasankha, N. Bahlis, S. Trudel, K. Weisel, C. Koenecke, A. Oriol, P. M. Voorhees, A. A. Alonso, N. S. Callander, M. V. Mateos Manteca, N. Reddy, S. Hakim, N. Patel, D. Williams, R. C. Jewell, X. Zhou, I. Gupta, A. K. Nooka
Diterbitkan 2022-06-01Dapatkan teks lengkap
Artikel -
2
P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRM... oleh A. Nooka, S. Lonial, S. Grosicki, M. Hus, K. Song, T. Facon, N. S. Callander, V. Ribrag, K. Uttervall, H. Quach, V. Vorobyev, C.-K. Min, S. Cheng, L. M. Smith, J. Yu, T. Collingwood, B. Holkova, B. E. Kremer, I. V. Gupta, P. G. Richardson, M. C. Minnema
Diterbitkan 2022-06-01Dapatkan teks lengkap
Artikel -
3
Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogen... oleh S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia
Diterbitkan 2020-09-01Dapatkan teks lengkap
Artikel